Piramal Pharma Limited (NSE:PPLPHARMA)
India
· Delayed Price · Currency is INR 214.84
+2.84 (1.34%)
May 13, 2025, 3:30 PM IST
Piramal Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Net Income | 178.2 | -1,865 | 3,760 | 7,708 |
| Depreciation & Amortization | 7,170 | 6,568 | 5,762 | 4,328 |
| Other Amortization | 235.5 | 199 | 99.7 | 129.32 |
| Loss (Gain) From Sale of Assets | 4.6 | 4.8 | 5.4 | -194.58 |
| Loss (Gain) From Sale of Investments | 4.8 | -25.6 | -231.3 | 7.94 |
| Stock-Based Compensation | 274.7 | - | - | - |
| Provision & Write-off of Bad Debts | 319 | 420.5 | 74.4 | 25.38 |
| Other Operating Activities | 4,202 | 2,558 | 1,117 | -769.2 |
| Change in Accounts Receivable | -3,914 | 892.6 | -1,852 | -4,758 |
| Change in Inventory | -5,318 | -1,726 | -1,756 | -823.94 |
| Change in Accounts Payable | 4,043 | -2,717 | 791.2 | 1,343 |
| Change in Other Net Operating Assets | 2,845 | 529.5 | -106 | -1,481 |
| Operating Cash Flow | 10,045 | 4,839 | 7,664 | 5,516 |
| Operating Cash Flow Growth | 107.60% | -36.86% | 38.94% | - |
| Capital Expenditures | -7,120 | -9,648 | -8,895 | -5,559 |
| Sale of Property, Plant & Equipment | 16 | 196.9 | 324.2 | - |
| Cash Acquisitions | -63.3 | -733.1 | -8,047 | -36,068 |
| Investment in Securities | 2,586 | -3,958 | -2,326 | -215.54 |
| Other Investing Activities | 241.3 | 754.1 | 822.7 | 489.32 |
| Investing Cash Flow | -4,340 | -13,388 | -18,121 | -41,353 |
| Short-Term Debt Issued | 14,206 | 18,219 | 22,536 | - |
| Long-Term Debt Issued | 2,401 | 25,628 | - | - |
| Total Debt Issued | 16,607 | 43,847 | 22,536 | 23,509 |
| Short-Term Debt Repaid | -17,709 | -14,647 | -9,965 | - |
| Long-Term Debt Repaid | -8,784 | -17,570 | -2,684 | - |
| Total Debt Repaid | -26,493 | -32,218 | -12,649 | -25,992 |
| Net Debt Issued (Repaid) | -9,886 | 11,629 | 9,887 | -2,483 |
| Issuance of Common Stock | 10,500 | - | - | 39,078 |
| Common Dividends Paid | - | -670 | -500 | - |
| Other Financing Activities | -4,837 | -2,781 | -1,445 | -577.75 |
| Financing Cash Flow | -4,224 | 8,178 | 7,942 | 36,709 |
| Foreign Exchange Rate Adjustments | 177.9 | 51.5 | -20.4 | 38.95 |
| Miscellaneous Cash Flow Adjustments | - | - | 767.4 | 104.49 |
| Net Cash Flow | 1,660 | -319.5 | -1,768 | 1,016 |
| Free Cash Flow | 2,925 | -4,809 | -1,231 | -42.55 |
| Free Cash Flow Margin | 3.58% | -6.79% | -1.83% | -0.07% |
| Free Cash Flow Per Share | 2.28 | -4.04 | -1.04 | -0.07 |
| Cash Interest Paid | 4,696 | 2,781 | 1,445 | 1,509 |
| Cash Income Tax Paid | 1,568 | 1,890 | 1,694 | 1,334 |
| Levered Free Cash Flow | -1,166 | -8,740 | -8,823 | - |
| Unlevered Free Cash Flow | 1,627 | -6,630 | -7,643 | - |
| Change in Net Working Capital | 1,808 | 3,470 | 8,111 | - |
Updated Jan 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.